O. Yu

First name

O.

Last name

Yu

Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., et al. (2024). Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. Bmj, 385, e078242. http://doi.org/10.1136/bmj-2023-078242

View

Pradhan, R., Yin, H., Yu, O., & Azoulay, L. (2022). Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc21-1953

View

Pradhan, R., Yu, O., Platt, R. W., & Azoulay, L. (2022). Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract, 185, 109229. http://doi.org/10.1016/j.diabres.2022.109229

View

Yu, O., Azoulay, L., Yin, H., Filion, K. B., & Suissa, S. (2018). Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Am J Med. http://doi.org/10.1016/j.amjmed.2017.09.044

View